Photo of Matthew J Frigault, MD

Matthew J Frigault, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 643-6175


mfrigault@mgb.org

Photo of Matthew J Frigault, MD

Massachusetts General Hospital
Phone: (617) 643-6175


mfrigault@mgb.org

Visualize Collaborations

Matthew J Frigault, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Clinical Director - Cellular Immunotherapy Program, BMT & Cellular Therapy, Massachusetts General Hospital

HCC PROGRAM AFFILIATION

HCC ASSOCIATIONS

  • Co-Associate Director, Clinical Trials, Executive Committee
  • Member, Center Scientific Council

Research Abstract

My primary research efforts involve translating new and evolving cellular therapy products into patients while also gaining a better understanding of the immunologic mechanisms of efficacy, toxicity and resistance. My previous work has included translational aspects of cellular therapy biology and signaling while at the University of Pennsylvania and development of next generation CAR-T cell constructs and their execution into first in human studies.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Frigault MJ, Maziarz RT, Amoloja T, Burke L, Bhatt V, Moskop A, Pasquini M, DiPersio JF. Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Dat Transplant Cell Ther 2026. PubMed
  • Roberts TJ, Meador CB, Fuld AD, Lasko A, Frigault M, Hangar KM, Reynolds K, Sadow PM, Wirth LJ. A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib. Thyroid 2026. PubMed
  • Liu KJ, Zhang L, Zhou B, Hong JS, Pak A, Yee AJ, Raje NS, Frigault MJ, Maus MV, Barmettler S. Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy. Transplant Cell Ther 2026. PubMed
  • Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I. Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma. Blood 2026. PubMed
  • Scarpetti L, Schwartz DE, Huang W, Ikeda D, Collier K, Chung J, DeFilipp Z, El-Jawahri A, Frigault MJ, McAfee S, Newcomb R, Spitzer TR, O'Donnell P, Chen YB. Incidence of and Risk Factors for Delayed Engraftment after Post-Transplant Cyclophosphamide. Transplant Cell Ther 2026. PubMed
  • Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, Cirstea DD, Harris DL, Bozym DJ, Puliafito BR, Newcomb RA, Dhawale TM, Johnson PC, El-Jawahri A, Jeffrey R, Barselau A, Li A, Emmanuel-Alejandro E, Cook D, Lindell KA, Luk SO, Chaffee R, Yee AJ, Branagan AR, Raje NS, Graham C, Hammond SP, Bushman FD, Roche AM, Reddy S, McFarland AG, Chen YB, Choi BD, Mount CW, Dougan M, Nardi V, Sohani A, Gallagher KME, Maus MV, Frigault MJ, Leick MB. Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea. Blood 2026. PubMed
  • Ababneh HS, Yee AJ, Raje NS, Frigault MJ, Johnson PC, Patel CG. Outcomes of combined bispecific antibody and radiation therapy in relapsed/refractory hematologic malignancies. Radiother Oncol 2026; 217:111386. PubMed
  • Locke FL, Nikiforow S, Frigault MJ, Maloney DG, Davila M, Miklos DB, Lin Y, Vong J, Shah NN, Neelapu SS, Welch J, Ng E, Jacobson C, Maus MV. Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies. Transplant Cell Ther 2025. PubMed
  • Hunter BD, Lunning M, Shadman M, Ahmed S, Abramson JS, Perales MA, Ahmed N, Mirza AS, Isufi I, Frigault MJ, Crombie JL, Miklos DB, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini MC, Kamdar M. CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplant Cell Ther 2025. PubMed
  • Itzhaki Ben Zadok O, Simitsis P, Jacobson C, Nadeem O, Frigault MJ, Raje N, Duffy C, Costello P, Cruz JD, Looka A, Nohria A. Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy. British Journal of Haematology 2025. PubMed
  • Meyer T, Finn RS, Borad M, Mahipal A, Edeline J, Houot R, Hausner PF, Hollebecque A, Goyal L, Frigault M, Jeffry Evans TR, Wong KM, Tan BR, Mitry E, Sarker D, Feun L, El-Rayes B, Thistlethwaite F, Kaseb A, Alese O, Jin Z, Cirillo C, Bruix J, Roddie C, Noto P, Fayngerts S, Cristiani S, Sampson J, Bai J, Isabelle M, Broad R, Sun A, Norry E, Sangro B. Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma. J Hepatol 2025. PubMed
  • Smith CC, Chung J, El-Jawahri A, Frigault MJ, McAfee S, Newcomb RA, O'Donnell PV, Spitzer TR, Westervelt P, Chen YB, DeFilipp Z. Safe and effective addition of ruxolitinib to graft-versus-host prophylaxis in older adults undergoing reduced-intensity allogeneic hematopoietic cell transplantation. Transplant Cell Ther 2025. PubMed
  • Kaulen LD, Martinez-Lage M, Abramson JS, Karschnia P, Doubrovinskaia S, Shankar GM, Choi BD, Ramundo CM, Ehret F, Barnes JA, El-Jawahri A, Hochberg E, Johnson PC, Soumerai JD, Plotkin SR, Batchelor TT, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J. Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy. Blood 2025. PubMed
  • Ramapriyan R, Barker FG, Richardson LG, Sun J, Vandecandelaere G, Shim JM, De Vlaminck G, Gaffey M, Grewal EP, Tazhibi M, Morshedy K, Aref AR, Batool SM, Guo X, Ijad N, Balaj L, Wakimoto H, Martinez-Lage M, Frigault MJ, Leick MB, Bernstock JD, Bi WL, Carter BS, Chiocca EA, Dietrich J, Gerstner ER, Boland GM, Nahed BV, Plotkin SR, Jenkins RW, Brastianos PK, Curry WT, Maus MV, Choi BD. Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells. 2025. PubMed
  • Little JS, Medina Pena A, Kim EB, Yee AJ, Nadeem O, Midha S, Sperling AS, Munshi NC, Raje NS, Frigault MJ, Cirstea DD, Hammond SP. Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy. Blood Adv 2025. PubMed
  • Shune L, Frigault MJ, Riedell PA. CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges. J Immunother Cancer 2025. PubMed
  • Haugh A, Frigault MJ. Cytokines and immune effector cell therapy. Best Pract Res Clin Haematol 2025; 38:101628. PubMed
  • Ababneh HS, Ng AK, Wan J, Walburn T, Zhu L, Bobić M, Johnson PC, Bredtfeld J, Leeman J, Soumerai J, Abramson JS, Barnes J, Takvorian R, Frigault MJ, Pursley J, Patel CG. 5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma. Int J Radiat Oncol Biol Phys 2025. PubMed
  • Blumenberg V, Puliafito BR, Graham CE, Leick MB, Chowdhury MR, King M, Harris DL, Raje NS, Branagan AR, Yee AJ, Cirstea DD, Gallagher KME, Dietrich J, Maus MV, Frigault MJ. Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment. Blood 2025. PubMed
  • DeFilipp Z, Kim HT, Knight LW, O'Connor SM, Dhaver SE, White M, Dholaria B, Schroeder MA, Vasu S, Abedin SM, Chung J, El-Jawahri A, Frigault MJ, McAfee SL, Newcomb RA, O'Donnell PV, Spitzer TR, Chen YB, Hobbs GS. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood 2025. PubMed
  • Frigault MJ, Maziarz RT, Park JH, Lazaryan A, Shah NN, Svoboda J, Lekakis LJ, Reshef R, Phillips CL, Burke L, Lei J, Pratta M, Morariu-Zamfir R, DiPersio JF. Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study. Blood 2025. PubMed
  • Locke FL, Mahmoudjafari Z, Kebriaei P, Gardner RA, Frigault MJ, Frey N, Komanduri KV, Perales MA, Nikiforow S. Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells. Transplant Cell Ther 2025. PubMed
  • Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch RC, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared JA, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik AP, Hill BT, Kamdar M, Ortiz-Maldonado V, Martínez-Cibrian N, Shune L, Shadman M. Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. Blood 2025. PubMed
  • Frigault MJ, Yao E, Berger TR, Wehrli M, Gallagher KME, Horick N, Graham CE, Jacobson CA, Chen YB, Leick MB, DeFilipp Z, El-Jawahri A, Johnson PCC, Dolaher M, Katsis K, Kim AI, Crombie JL, Merryman RW, Cook D, Trailor M, Cho H, Jeffrey R, Shen RR, Filosto S, Nater J, Getz G, Haradhvala NJ, Maus MV. Single-cell dynamics of breakthrough toxicities following anakinra prophylaxis for axicabtagene ciloleucel in lymphoma. Blood Adv 2025. PubMed
  • Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ. Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer 2025. PubMed
  • Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia 2025. PubMed
  • Ababneh HS, Frigault MJ, Ng AK, Patel CG. Post-CAR T-Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B-Cell Lymphoma. Hematol Oncol 2025; 43:e70025. PubMed
  • Ellithi M, Elsallab M, Lunning MA, Holstein SA, Sharma S, Trinh JQ, Ma J, Maus MV, Frigault MJ, D'Angelo CR. Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data. Transplant Cell Ther 2024. PubMed
  • Somasundaram E, Gill R, Hartford N, Collier K, McAfee SM, Dey Bimalangshu R, El-Jawahri A, DeFilipp Z, Frigault M, Leick M, Newcomb R, O'Donnell PV, Chen YB, Spitzer TR. Factors Associated With Increased Risk of Contamination in Bone Marrow Transplants. Transplant Cell Ther 2024. PubMed
  • Sutherland NM, Zhou B, Zhang L, Ong MS, Hong JS, Pak A, Liu KJ, Frigault MJ, Maus MV, Hill JA, Reynolds K, Walter JE, Camargo CA, Barmettler S. Association of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality. J Allergy Clin Immunol 2024. PubMed
  • Kaulen LD, Karschnia P, Doubrovinskaia S, Abramson JS, Martinez-Lage M, Shankar G, Choi BD, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J. Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis. Am J Hematol 2024. PubMed
  • Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J 2024; 14:108. PubMed
  • Ababneh HS, Ng AK, Frigault MJ, Jacobson CA, Patel CG. Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. Am J Hematol 2024. PubMed
  • Frigault MJ, Graham CE, Berger TR, Ritchey JK, Horick N, El-Jawahri A, Scarfò I, Schmidts A, Haradhvala N, Wehrli M, Lee WH, Parker A, Wiggin HR, Bouffard AA, Dey A, Leick MB, Katsis K, Elder EL, Dolaher M, Cook D, Chekmasova AA, Huang L, Nikiforow S, Daley H, Ritz J, Armant M, Preffer F, DiPersio JF, Nardi V, Chen YB, Gallagher KME, Maus MV. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood 2024. PubMed
  • Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek AE, Riedell PA, Awan F, Samples L, Shadman M, Hu M, Bachanova V, Wesson W, Ahmed N, Iqbal M, Kharfan-Dabaja MA, Scordo M, Johnson PC, Chen YB, Ito S, Hamadani M, Frigault M. Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. Am J Hematol 2024. PubMed
  • Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Christensen JH, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV. Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clin Cancer Res 2024; 30:2286. PubMed
  • Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez A. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. Leukemia 2024. PubMed
  • Grauwet K, Berger T, Kann MC, Silva H, Larson R, Leick MB, Bailey SR, Bouffard AA, Millar D, Gallagher K, Turtle CJ, Frigault MJ, Maus MV. Stealth transgenes enable CAR-T cells to evade host immune responses. J Immunother Cancer 2024. PubMed
  • Newcomb RA, Gao L, Vanderklish J, Tse A, Saylor M, Danielson C, Wali N, Frigault M, McAfee S, Spitzer T, DeFilipp Z, Chen YB, Amonoo HL, El-Jawahri A. Outcomes of a Formal Hematopoietic Cell Transplantation Survivorship Program on Screening for Late Effects. Transplant Cell Ther 2024. PubMed
  • Elsallab M, Ellithi M, Lunning MA, D'Angelo C, Ma J, Perales MA, Frigault MJ, Maus MV. Second Primary Malignancies After Commercial CAR T Cell Therapy: Analysis of FDA Adverse Events Reporting System (FAERS). Blood 2024. PubMed
  • Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med 2024. PubMed
  • DeFilipp Z, Damania AV, Kim HT, Chia-Chi C, El-Jawahri A, McAfee SL, Bottoms AS, Toncheva V, Smith MM, Dolaher M, Perry LS, White M, Diana B, Connolly S, Dey BR, Frigault MJ, Newcomb RA, O'Donnell PV, Spitzer TR, Mansour MK, Weber D, Ajami NJ, Hohmann E, Jenq RR, Chen YB. Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract. Blood Adv 2024. PubMed
  • Lee WH, Graham CE, Wiggin HR, Nolan HK, Graham KJ, Korell F, Leick MB, Barselau AL, Emmanuel-Alejandro E, Trailor MA, Gildea JM, Preffer F, Frigault MJ, Maus MV, Gallagher KME. Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood. 2024. PubMed
  • Johnson PC, Neckermann I, Sadrzadeh H, Newcomb R, El-Jawahri AR, Frigault MJ. Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther 2024. PubMed
  • Walton ZE, Frigault MJ, Maus MV. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Expert Opin Pharmacother 2024; 25:263-279. PubMed
  • Ababneh HS, Frigault MJ, Ng AK, Patel CG. Radiation therapy as bridging and salvage strategy among patients with secondary central nervous system lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy. Hematol Oncol 2023. PubMed
  • Larson RC, Kann MC, Graham C, Mount CW, Castano AP, Lee WH, Bouffard AA, Takei HN, Almazan AJ, Scarfó I, Berger TR, Schmidts A, Frigault MJ, Gallagher KME, Maus MV. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nat Commun 2023; 14:7509. PubMed
  • Ikeda DJ, DeFilipp Z, Collier K, Chen YB, Dey BR, El-Jawahri A, Frigault MJ, Leick MB, McAfee SL, Newcomb RA, O'Donnell PV, Spitzer TR. Low incidence of engraftment syndrome following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant 2023. PubMed
  • Ababneh HS, Ng AK, Abramson JS, Soumerai JD, Takvorian RW, Frigault MJ, Patel CG. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma. Hematol Oncol 2023. PubMed
  • Ababneh HS, Yee AJ, Raje NS, Martin S, Frigault MJ, Ng AK, Patel CG. Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy. Radiother Oncol 2023; 189:109933. PubMed
  • Little JS, Tandon M, Hong JS, Nadeem O, Sperling AS, Raje N, Munshi N, Frigault M, Barmettler S, Hammond SP. Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Adv 2023; 7:5485-5495. PubMed
  • Ababneh HS, Frigault MJ, Patel CG. Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy. Hematol Oncol 2023. PubMed
  • Ryan CE, Zon RL, Redd R, Fisher DC, Shouval R, Kumar A, Crombie JL, Sadrzadeh H, Kim AI, Nayak L, Chukwueke UN, Jacobson CA, Frigault MJ, Palomba ML, Armand P, Epstein-Peterson Z, Merryman RW. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. British Journal of Haematology 2023. PubMed
  • Eckhardt CA, Sun H, Malik P, Quadri S, Santana Firme M, Jones DK, van Sleuwen M, Jain A, Fan Z, Jing J, Ge W, Danish HH, Jacobson CA, Rubin DB, Kimchi EY, Cash SS, Frigault MJ, Lee JW, Dietrich J, Westover MB. Automated detection of immune effector cell-associated neurotoxicity syndrome via quantitative EEG. Ann Clin Transl Neurol 2023. PubMed
  • Karschnia P, Miller KC, Yee AJ, Rejeski K, Johnson PCC, Raje N, Frigault MJ, Dietrich J. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T-cells. Blood 2023. PubMed
  • Graham CE, Lee WH, Wiggin HR, Supper VM, Leick MB, Birocchi F, Yee AJ, Petrichenko A, Everett JK, Bushman FD, Sadrzadeh H, Rapalino O, Chiu D, Arrillaga-Romany IC, Maus MV, Frigault MJ, Gallagher KME. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 2023. PubMed
  • Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich J. Neurotoxicity and management of primary and secondary CNS lymphoma after adoptive immunotherapy with CD19-directed CAR T-cells. 2023. PubMed
  • Ababneh HS, Ng AK, Frigault MJ, Abramson JS, Johnson PC, Jacobson CA, Patel CG. Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR Tcell therapy. Haematologica 2023. PubMed
  • Mahmood SS, Riedell PA, Feldman S, George G, Sansoterra SA, Althaus T, Rehman M, Mead E, Liu JE, Devereux RB, Weinsaft JW, Kim J, Balkan L, Barbar T, Lee Chuy K, Harchandani B, Perales MA, Geyer MB, Park JH, Palomba ML, Shouval R, Tomas AA, Shah GL, Yang EH, Gaut DL, Rothberg MV, Horn EM, Leonard JP, Van Besien K, Frigault MJ, Chen Z, Mehrotra B, Neilan TG, Steingart RM. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J 2023; 44:2029-2042. PubMed
  • Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Transplant Cell Ther 2023. PubMed
  • Dhawale TM, Johnson PC, Gaballa MR, Nelson AM, Lavoie MW, Boateng KY, Greydanus C, Frigault MJ, El-Jawahri A. Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy. Cancer 2023; 129:441-449. PubMed
  • Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL. Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies. Transplant Cell Ther 2023. PubMed
  • Frigault M, Rotte A, Ansari A, Gliner B, Heery C, Shah B. Dose fractionation of CAR-T cells. A systematic review of clinical outcomes. J. Exp. Clin. Cancer Res. 2023; 42:11. PubMed
  • Schmidts A, Srivastava AA, Ramapriyan R, Bailey SR, Bouffard AA, Cahill DP, Carter BS, Curry WT, Dunn GP, Frigault MJ, Gerstner ER, Ghannam JY, Kann MC, Larson RC, Leick MB, Nahed BV, Richardson LG, Scarfò I, Sun J, Wakimoto H, Maus MV, Choi BD. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma. 2023; 5:vdac185. PubMed
  • Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B. Dose-response correlation for CAR-T cells: a systematic review of clinical studies. J Immunother Cancer 2022. PubMed
  • Jones DK, Eckhardt CA, Sun H, Tesh RA, Malik P, Quadri S, Firme MS, van Sleuwen M, Jain A, Fan Z, Jing J, Ge W, Nascimento FA, Sheikh IS, Jacobson C, Frigault M, Kimchi EY, Cash SS, Lee JW, Dietrich J, Westover MB. EEG-based grading of immune effector cell-associated neurotoxicity syndrome. Sci Rep 2022; 12:20011. PubMed
  • Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M, . UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol 2022; 9:e833-e843. PubMed
  • Miller KC, Johnson PC, Abramson JS, Soumerai JD, Yee AJ, Branagan AR, O'Donnell EK, Saucier A, Jacobson CA, Frigault MJ, Raje NS. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J 2022; 12:146. PubMed
  • Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, Utro F, Levovitz C, Jacobs RA, Slowik K, Danysh BP, Livak KJ, Parida L, Ferry J, Jacobson C, Wu CJ, Getz G, Maus MV. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med 2022; 28:1848-1859. PubMed
  • Hanna P, Strohbehn I, Moreno D, Harden D, Seethapathy H, Gupta S, Lee M, Ouyang T, Frigault M, Sise ME. Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma. Bone Marrow Transplant 2022. PubMed
  • Hanna P, Strohbehn I, Wang Q, Frigault M, Sise ME. Acute kidney injury caused by haplostorm after allogenic hematopoietic stem cell transplant. Bone Marrow Transplant 2022. PubMed
  • Frigault MJ, Bishop MR, Rosenblatt J, O'Donnell E, Raje N, Cook D, Yee AJ, Logan E, Avigan D, Jakubowiak AJ, Shaw KL, Daley H, Nikiforow S, Griffin FM, Cornwell C, Shen A, Heery C, Maus MV. Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv 2022. PubMed
  • Leick MB, Silva H, Scarfò I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC, Jan M, Wehrli M, Grauwet K, Horick N, Frigault MJ, Maus MV. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 2022. PubMed
  • Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood 2022; 139:2306-2315. PubMed
  • Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, Ghobadi A, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. 2022; 12:818679. PubMed
  • Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, Heymach JV, Govindan R, Bachier C, Doger de Spéville B, Frigault MJ, Olszanski AJ, Lam VK, Hyland N, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou D, Pentony MM, Sanderson JP, Gerry A, Marks D, Bai J, Holdich T, Norry E, Fracasso PM. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 advanced non-small cell lung cancer. J Immunother Cancer 2022. PubMed
  • Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, DeFilipp Z, Horick N, O'Donnell P, Spitzer T, Dey B, Cook D, Trailor M, Lindell K, Maus MV, Frigault MJ. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer 2022. PubMed
  • Villalba JA, Maus MV, Frigault MJ, Zaffini R, Gandhi RT, Rosenberg ES, Siedner MJ. False-positive HIV testing in patients receiving lentivirus-based chimeric antigen receptor T-cell therapy: A case report, review of the literature and proposed recommendations. J Infect Dis 2021. PubMed
  • Gong J, Drobni ZD, Alvi RM, Murphy SP, Sullivan RJ, Hartmann SE, Gilman HK, Lee H, Zubiri L, Raghu VK, Karp-Leaf RS, Zafar A, Zlotoff DA, Frigault MJ, Reynolds KL, Neilan TG. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer 2021; 158:99-110. PubMed
  • Anandappa AJ, Hobbs GS, Dey BR, El-Jawahri A, Frigault MJ, McAfee SL, O'Donnell PV, Spitzer TR, Chen YB, DeFilipp Z. Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients. Oncologist 2021. PubMed
  • Johansson U, Gallagher K, Burgoyne V, Maus MV, Casey KS, Brini GG, Frigault MJ, Yam JY, Chavda N, Besley C, Lugthart S. Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories. 2021. PubMed
  • Trivedi H, Hamdani O, Thomas B, Richard J, Shah K, Raskina K, Zhang L, Madigan A, Fox M, Wander S, Frigault MJ, Alexander B, Srkalovic G. Patient with Lobular Carcinoma of the Breast and Activating AKT1 E17K Variant. Acta Med Acad 2021; 50:209-217. PubMed
  • Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv 2021; 5:1648-1659. PubMed
  • Gupta M, Burns E, Georgantas NZ, Thierauf J, Nayyar N, Gordon A, Jones S, Pisapia M, Sun Y, Burns RP, Velarde JK, Jordan JT, Frigault MJ, Nahed BV, Jones PS, Barker FG, Curry W, Gupta R, Batchelor TT, Romero J, Brastianos P, Marble H, Martinez-Lage M, Tateishi K, Lennerz JK, Dietrich J, Cahill D, Carter B, Shankar GM. A Rapid Genotyping Panel for Detection of Primary Central Nervous System Lymphoma. Blood 2021. PubMed
  • Johnson PC, Jacobson C, Yi A, Saucier A, Dhawale TM, Nelson A, Lavoie MW, Reynolds MJ, Topping CEW, Frigault MJ, El-Jawahri A. Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy. J Natl Compr Canc Netw 2021. PubMed
  • Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 2021. PubMed
  • Trujillo JA, Godfrey J, Hu Y, Huang J, Smith SM, Frigault MJ, DeFilipp Z, Appelbaum D, Pu Y, Feinberg N, Althaus T, Bishop MR, Riedell PA, Kline J. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood 2021. PubMed
  • Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W, . Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 2020; 396:1885-1894. PubMed
  • Spitzer TR, Kim SE, Cohen R, Mathews R, Li S, McAfee SL, Dey BR, El-Jawahri A, DeFilipp Z, Frigault M, O'Donnell P, Hunnewell C, Saylor M, Vanderklish J, Danielson C, Poliquin C, Chen YB. Declining bone marrow harvest quality over 24 years: a single institution experience. Bone Marrow Transplant 2020. PubMed
  • Meyerowitz EA, Sen P, Schoenfeld SR, Neilan TG, Frigault MJ, Stone JH, Kim AY, Mansour MK, . Immunomodulation as Treatment for Severe COVID-19: a systematic review of current modalities and future directions. Clin Infect Dis 2020. PubMed
  • Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 2020; 4:5414-5424. PubMed
  • Leick MB, Maus MV, Frigault MJ. Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. Mol Ther 2020. PubMed
  • Lee M, Strohbehn IA, Seethapathy HS, Rusibamayila N, Casey KS, Gupta S, Leaf DE, Frigault MJ, Sise ME. Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel. Am J Kidney Dis 2020. PubMed
  • Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, Kleinstiver BP, Joung JK, Maus MV. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. J Immunother Cancer 2020. PubMed
  • Venkataraman V, Casey KS, Onozato M, Cin PD, Nardi V, Amrein PC, Bergeron MK, Brunner AM, Fathi AT, Foster JE, Moran J, Graubert TA, Hock H, Hunnewell C, Frigault MJ, McAfee S, Hobbs GS. Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia 2020. PubMed
  • Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol 2020. PubMed
  • Maurer AK, Li S, Hunter BD, Luk SO, O'Donnell SE, Dey BR, El-Jawahri A, Frigault MJ, McAfee S, O'Donnell PV, Spitzer TR, Chen YB, DeFilipp Z. Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2020. PubMed
  • Alvi RM, Fradley MG, Frigault MJ, Locke FL, Neilan TG. Reply: Cardiac Events Associated With Chimeric Antigen Receptor T Cells (CAR-T): A VigiBase Perspective. J Am Coll Cardiol 2020; 75:2523-2524. PubMed
  • Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest 2020; 130:1586-1594. PubMed
  • Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O'Donnell EK, Jacobson CA, Motwani SS, Parikh SM, Curhan GC, Reynolds KL, Leaf DE, Sise ME. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis 2020. PubMed
  • Nardi V, Ku N, Frigault MJ, Dubuc AM, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Burke ME, Foster J, Dal Cin P, Maus MV, Fathi AT, Hock H. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv 2020; 4:106-111. PubMed
  • Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv 2020; 4:122-126. PubMed
  • Sokolov E, Karschnia P, Benjamin R, Hadden RDM, Elwes RCD, Drummond L, Amin D, Paiva V, Pennisi A, Herlopian A, Frigault M, Sanderson R, Inam S, Cole AJ, Dietrich J. Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity. BMJ Neurol Open 2020; 2:e000054. PubMed
  • Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 2020. PubMed
  • Frigault MJ, Nikiforow S, Mansour MK, Hu ZH, Horowitz MM, Riches ML, Hematti P, Turtle CJ, Zhang MJ, Perales MA, Pasquini MC. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood 2020; 136:137-139. PubMed
  • Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw 2020; 18:230-241. PubMed
  • Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Halvorsen YD, Thurber TK, Dagher Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza MA, Yinh JM, Bowman KA, Meyerowitz E, Zafar A, Drobni ZD, Bolster MB, Kohler M, D'Silva KM, Dau J, Lockwood MM, Cubbison C, Weber BN, Mansour MK, . Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med 2020. PubMed
  • Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, Hassan MZO, Bassily E, Rhea I, Ismail-Khan R, Mulligan CP, Banerji D, Lazaryan A, Shah BD, Rokicki A, Raje N, Chavez JC, Abramson J, Locke FL, Neilan TG. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol 2019; 74:3099-3108. PubMed
  • Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, Frigault MJ, Leick MB, Schmidts A, Sagert JG, Curry WT, Carter BS, Maus MV. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer 2019; 7:304. PubMed
  • Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv 2019; 3:3248-3260. PubMed
  • Leick M, Hunter B, DeFilipp Z, Dey BR, El-Jawahri A, Frigault M, McAfee S, Spitzer TR, O'Donnell P, Chen YB. Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. Bone Marrow Transplant 2019. PubMed
  • Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MV. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood 2019; 134:860-866. PubMed
  • Abramson JS, Irwin KE, Frigault MJ, Dietrich J, McGree B, Jordan JT, Yee AJ, Chen YB, Raje NS, Barnes JA, Davis B. Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer 2019. PubMed
  • Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol 2019; 37:1049-1058. PubMed
  • Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Haaber J, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV. Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19. Clin Cancer Res 2019. PubMed
  • Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw 2019; 17:255-289. PubMed
  • Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood 2019. PubMed
  • Scarfò I, Frigault MJ, Maus MV. CAR-Based Approaches to Cutaneous T-Cell Lymphoma. 2019; 9:259. PubMed
  • Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, Preffer FI, Weinstock DM, Maus MV. Anti-CD37 chimeric antigen receptor T cells are active against B and T cell lymphomas. Blood 2018. PubMed
  • Ormhøj M, Bedoya F, Frigault MJ, Maus MV. CARs in the Lead Against Multiple Myeloma. Curr Hematol Malig Rep 2017. PubMed
  • Bedoya F, Frigault MJ, Maus MV. The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. Mol Ther 2017; 25:314-320. PubMed
  • Frigault MJ, Maus MV. Chimeric antigen receptor-modified T cells strike back. Int Immunol 2016. PubMed
  • Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 2015; 3:356-67. PubMed
  • Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD, Scholler J, Scholler N, Bonneau R, June CH. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 2014; 124:1070-80. PubMed
  • Frigault MJ, June CH. Predicting cytokine storms: it's about density. Blood 2011; 118:6724-6. PubMed
  • Bellin RM, Kubicek JD, Frigault MJ, Kamien AJ, Steward RL, Barnes HM, Digiacomo MB, Duncan LJ, Edgerly CK, Morse EM, Park CY, Fredberg JJ, Cheng CM, LeDuc PR. Defining the role of syndecan-4 in mechanotransduction using surface-modification approaches. Proc Natl Acad Sci U S A 2009; 106:22102-7. PubMed
Hide
Visualize Collaborations